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ABSTRACT
Calcitriol (1 , 25-dihydroxyvitamin D 3) induces the expression of CD14 in mononuclear phagocytes. The mechanisms
accounting for this have been unclear since the promoter of  CD14  does not contain a canonical vitamin D response
element (VDRE). Calcitriol has been shown to regulate the activity of the transcription factor Sp-1 and our analysis of
the proximal promoter of CD14 indicated the presence of four Sp-1-like binding sequences. To identify which of these
sites might be involved in the response to calcitriol, we used a system incorporating an electrophoretic mobility shift
assay (EMSA) coupled to Western blot analysis (WEMSA). Using WEMSA, we found that only one of the Sp-1-like
binding sequences, located at position -91 to -79 (relative to the transcription start site), bound the transcription factor
Sp1. Sp-1 binding to this site was demonstrable using nuclear extracts from control cells. Notably, binding activity was
attenuated  in  nuclear  extracts  prepared  from cells  that  had  been  incubated  with  calcitriol,  thus  suggesting  Sp-1
involvement in calcitriol induction of  CD14 expression. Notably, these results show that like EMSA, WEMSA can be
broadly applied to aid in the identification of transcription factors involved in regulating gene expression. WEMSA,
however,  offers  a  number  of  distinct  advantages  when  compared  with  conventional  EMSA.  Antibodies  used  for
WEMSA often provide less ambiguous signals than those used in EMSA, and these do not have to recognize epitopes
under native conditions. In addition, WEMSA does not require the use of labeled oligos, thus eliminating a significant
expense associated with EMSA. 
INTRODUCTION
The regulation of gene expression in mammalian cells is
controlled by approximately 200 transcription factors that
interact with distinct DNA binding sites (1). Transcription
factors  (TF)  are  proteins  involved  in  the  negative  and
positive regulation of gene expression. Their mechanisms
of  action  may  involve  either  direct  binding  to  specific
DNA sequences  in promoter regions of  target  genes,  or
indirect  effects  on  gene  expression  through  interactions
with other proteins directly bound to DNA elements. Each
TF is defined by the short DNA sequences that reflects its
DNA  binding  motif  (2).  TFs  usually  consist  of  two
functional  domains,  a  DNA  binding  domain  and  a
regulatory domain that interacts with components of the
transcription initiation complex and regulatory proteins,
thereby  affecting  the  efficiency  of  DNA  binding  and
transcription.  Typically,  gene  promoters  contain  several
functional TF-DNA binding sites and in most cases, there
is more than one specific DNA binding site for a particular
© 2008 by Biological Procedures Online. This paper is Open Access. Copying, printing, redistribution and storage permitted. Journal © 1997-2008
Biological Procedures Online - www.biologicalprocedures.com
30
TF  (3).  In  addition,  promoters  of  human  genes  contain
many transcription  factor  binding elements  that  have  a
varied  range  of  identities  when  compared  to  canonical
transcription factor binding elements (4).
Calcitriol  induces  monocyte  differentiation  and  this  is
reflected in increased surface expression of both CD14 and
CD11b (5). Since no canonical vitamin D response element
(VDRE) has been identified in the human CD14 promoter,
the mechanism of CD14 activation in response to calcitriol
is  unclear.  Recently,  the  transcription  factor  CREB  has
been shown to be activated by calcitriol and to play a role
in the regulation of  CD14 expression (6). It has also been
reported that  calcitriol  modulates  Sp-1  activity  and this
too may be  involved in regulating  CD14 expression (7).
Sp-1 belongs to a family of transcription factors that bind
to  GC-rich sequences  and is  involved in regulating  cell
growth, apoptosis and angiogenesis (reviewed in 8). Our
analysis  of  the  proximal  promoter  of  human  CD14
identified four candidate Sp-1-like sequences. This raised
the  question  of  which,  if  any,  of  these  sequences  is
involved in regulating the CD14 response to calcitriol. 
Conventionally,  electrophoretic  mobility  shift  assays
(EMSA) combined with antibody supershifts are used to
investigate  the  interactions  of  TFs  with  specific  DNA
elements (9). EMSAs are carried out using short synthetic
labeled  DNA  probes  corresponding  to  TF  binding
sequences in the promoter region of the gene of interest.
These  probes  are  then  incubated  with  crude  nuclear
extracts followed by the electrophoretic separation of the
resulting  protein-DNA mixture  on  a  polyacryamide  or
agarose gel in a low ionic strength buffer which results in
a  mobility  shift.  In  general,  an  antibody-  mediated
supershift  is  then  used  to  confirm  the  identity  of  the
particular TF involved. In most situations, canonical DNA
probes are used for EMSA analysis. However, variability
in the DNA binding sequences recognized by TF binding
domains  may  complicate  the  results.  While  supershifts
can be highly informative, they have limitations. In many
supershift assays for example, multiple bands are present
which  may  be  diffuse  and  difficult  to  interpret.  In
addition, antibodies capable of mediating a supershift for
a particular transcription factor of interest may not always
be  available  because  of  the  requirement  that  they
recognize epitopes under native conditions (10). The very
nature of the supershift assay itself also does not allow the
re-use  of  antibodies,  thus  making  this  technique
somewhat  costly.  Moreover,  EMSA-based  supershift
assays are carried out in a manner such that they do not
permit examination of multiple TFs simultaneously. In a
previous  report,  we  used  a  modification  of  EMSA  to
incorporate  Western  blotting  in  a  combined  approach
which we referred to as WEMSA (6).  The present study
again utilizes WEMSA to examine the regulation of Sp-1
binding to the promoter region of CD14 in myeloid cells in
response to calcitriol. The findings reported illustrate the
general  applicability  of  WEMSA  to  identify  active
sequences  in  gene  promoters  and  their  cognate  DNA
binding proteins. Because Western blotting is incorporated
in this assay, the recycling of antibodies is possible in most
situations and this significantly reduces the cost normally
associated  with  classical  supershift  assays.  Moreover,
suitable  antibodies  for  WEMSA  are  more  generally
available  since  there  is  no  requirement  that  they  must
recognize epitopes under native conditions. Importantly,
WEMSA also has the advantage of not requiring the use of
labeled  oligos  needed  for  EMSA.  This  along  with  the
advantages  outlined  above,  makes  this  technique  an
attractive alternative to classical EMSA to study the roles
of transcription factors in regulating gene expression. 
MATERIALS AND METHODS
Reagents and Chemicals
1 ,25-dihydroxyvitamin D 3 (calcitriol), was obtained from
Calbiochem  Corporation  (San  Diego,  CA).  RPMI  1640,
Hanks  Balanced  Salt  Solution  (HBSS),
penicillin/streptomycin, protease inhibitor cocktail, PMSF,
and poly (dI-dC)  were purchased from Sigma Chemical
Co.  (St.  Louis,  MO).  Nitrocellulose  membranes  were
obtained  from  Bio-Rad  Laboratories  (Hercules,  CA).
Unlabelled and labelled Sp-1-like oligos for WEMSA and
EMSA were from Invitrogen (Carlsbad,  CA).  Unlabelled
and labelled canonical  Sp-1 oligos were purchased from
Panomics.  Anti-Sp-1  antibody  was  from  Upstate  Cell
Signaling Solutions (Lake Placid, NY). 
Cell Culture
The human promonocytic cell line THP-1 (acquired from
the  American  Type  Culture  Collection,  Rockville,  MD)
was  cultured at  37°C /  5% CO2 in  RPMI  1640  medium
supplemented with 10% (v/v) heat-inactivated fetal bovine
serum  (FBS),  penicillin  (100  units/ml)  and  streptomycin
(100 g/ml). For most experiments, prior to use, cells were
washed in HBSS and incubated for 5 h in RPMI/0.5% FBS
for serum starvation. 
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Preparation of Nuclear and Cytoplasmic Fractions
Nuclear and cytoplasmic fractions were prepared based
on a protocol from the Skirball Institute of Biomolecular
Medicine,  NYU  Medical  Center  (6)  with  minor
modifications. Briefly, approximately 2 x 107 THP-1 cells
were  used per  assay  and after  treatment  the  cells  were
washed twice with HBSS and collected by centrifugation.
Subsequent steps were performed on ice. The cells were
resuspended  in  300  l  of  fractionation  buffer  (10  mM
HEPES pH 7.9 containing 50 mM NaCl, 0.5 M sucrose, 0.1
mM EDTA, 0.5% Triton-X 100, 1 mM DTT, 10 mM sodium
pyrophosphate, 2 mM NaF, 17.5 mM -glycerophosphate,
1 mM PMSF and 4 g/ml aprotinin, 2 g/ml pepstatin A, 
and 2 g/ml leupeptin  and incubated on ice for 5  min.
Nuclei were collected at 4500 x g for 5 min at 4°C. Nuclei
were washed and resuspended in 500 l buffer A (10 mM
HEPES pH 7.9 containing 10 mM KCl, 0.1 mM EDTA, 0.1
mM  EGTA,  1  mM  DTT,  1  mM  PMSF,  and  4  g/ml
aprotinin,  2  g/ml  pepstatin  A,  and 2  g/ml  leupeptin) 
and pelleted at 4500 x g for 5 min at 4°C. Nuclear pellets
were resuspended in 40 l of buffer B (10 mM HEPES pH
7.9, 500 mM NaCl, 0.1  mM EDTA, 0.1  mM EGTA, 0.1%
IGEPAL,1 mM DTT, 1 mM PMSF, and 4 g/ml aprotinin, 2
g/ml pepstatin A, and 2 g/ml leupeptin  ) and mixed by
extensive vortexing over 10-15 min at room temperature.
Tubes  were  kept  cold  by  placing  them  on  ice
intermittently during vortexing. Samples were centrifuged
at  11,600  x  g for  20  min  at  4°C  and  supernatants
representing crude nuclear extracts were then transferred
to new tubes and adjusted to a final concentration of 10%
glycerol. The aliquots were stored at -70°C. 
Preparation of the Oligonucleotides
The  promoter  of  CD14 was  analyzed  by  TFSEARCH
software  (http://www.cbrc.jp/research/db/TFSEARCH.html)
and  four  different  candidate  Sp-1  sequences  were
identified.  Synthesized  solutions  of  sense  and  antisense
oligonucleotides were prepared at 10 M concentration in
20 mM Tris pH 8.0. Sense and antisense oligos were then
annealed by heating at 95°C for 5 min and cooled to room
temperature for 15 min before storage at -20°C.
Electrophoretic-Mobility Shift Assay
2-5 g of nuclear extract was used for EMSA according to
the  manufacturers  instructions  (Panomics,  EMSA  Gel-
Shift  Kit).  Briefly,  nuclear  extracts  containing  equal
amounts of protein for each sample were incubated with
poly (dI-dC) (1 g/ l) for 5 min, followed by the addition 
of binding buffer (20 mM HEPES pH 7.9, 1 mM DTT, 0.1
mM EDTA, 50 mM KCl, 5% glycerol and 200 g/ml BSA)
and biotinylated oligo (10 ng/ l). To control for specificity
of binding,  for selected samples, a 5-fold excess of non-
labeled  oligo  was  added  prior  to  the  addition  of  the
biotinylated  probe.  Binding  reaction  mixtures  were
incubated for 30 min at room temperature. Protein-DNA
complexes  were  separated  on  5%  nondenaturing
polyacrylamide  gels  in  Tris-borate/EDTA buffer  (0.1  M
Tris,  0.09  M  boric  acid  containing  1mM  EDTA)  at  4°C.
After  electrophoresis,  gels  were  transferred  to  nylon
membranes. Transferred oligos were immobilized by UV
crosslinking  for  3  min.  For  detection  of  bound  oligos,
membranes were blocked using blocking buffer (Panomics
EMSA  Gel-Shift  Kit)  followed  by  the  addition  of
Streptavidin-HRPO  and  blots  were  developed  by  ECL
according to the manufacturers instructions (Amersham,
Arlington  Heights,  IL,  U.S.A.).  Commercially  available
biotinylated oligonucleotide  encoding the  Sp-1  motif  5'-
ATTCGATCGGGGCGGGGCGAG-3'  was  used  as  a
canonical probe (Panomics, AY-1043).
Combined EMSA and Western blotting (WEMSA)
For this assay we used custom synthesized non-labeled,
oligonucleotides encoding the Sp-1-like binding sequences
located within the  proximal  promoter  of  CD14 (Fig.  1).
The  Sp-1-like  oligos  were  as  follows:  (1)  5'-
GGGGGGTTGG-3'  at  position  -345  to  -336,  (2)  5'-
GTCCCTCCCCCT-3'  at  position  -159  to  -148  ,  (3)  5'-
AGGGGGCTGGC-3'  at  position  -113  to  -100  and (4)  5'-
AGAGGTGGGGAGG-3'  at position -91 to  -79 .  WEMSA
was  performed essentially  as  described above,  with  the
exception  that  separated  DNA-protein  complexes  were
transferred to  nitrocellulose  membrane instead of  nylon
membrane  and  probed  with  anti-Sp-1  for  Western
blotting. Blots were developed by ECL. 
RESULTS AND DISCUSSION
The Screening for Calcitriol-Regulated Binding of Sp-1 to
DNA Response Elements in Human CD14 by WEMSA
In  many gene  promoters  it  is  possible  to  find  multiple
candidate  binding  sites  for  any  particular  transcription
factor.  Prior  analysis  of  the  human  CD14 promoter
indicated five CRE-like sites (6) and four candidate Sp-1
sites  (sequences  1-4  in  Fig.  1).  These  four  sites  show
70-85% homology with canonical Sp-1-binding sequences.
Using conventional EMSA, four labeled-oligonucleotides
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based on  each  of  these  putative  sites  would have  been
required to examine which, if any, were involved in Sp-1
binding.  On  the  other  hand,  WEMSA does  not  require
labeling  of  oligonucleotides  as  identification  of  the  TF
involved  is  based  on  Western  blotting  using  specific
antibodies.  To  evaluate  further  the  effectiveness  of
WEMSA in screening for candidate DNA binding sites of a
transcription  factor  of  interest,  oligonucleotides  were
synthesized based on the four Sp-1-like sequences in the
human  CD14 promoter.  THP-1  cells  were  treated  with
calcitriol  and  nuclear  extracts  were  prepared  and
incubated  with  these  four  Sp-1-like  sequences
independently.  DNA-protein  complexes  were  then
separated by 5% polyacrylamide gel electrophoresis, and
separated  DNA-protein  complexes  were  transferred  to
nitrocellulose  membranes  for  immunodetection  of  Sp-1.
The results shown in Fig. 2 indicate that Sp-1 bound to
only  one  of  the  four  candidate  Sp-1  sites.  This  Sp-1
binding  site  (5'-AGAGGTGGGGAGG-3')  located  at
positions -91 to  -79 within the  CD14 promoter  has 85%
identity  to  the  canonical  Sp-1  sequence  (5'-
ATTCGATCGGGGCGGGGCGAG-3'). Sp-1 binding to this
site  was  apparent  in  nuclear  extracts  from  cells  in  the
basal state and binding activity was negatively regulated
by  calcitriol.  Whereas  conventional  Western  blotting  of
nuclear extracts detected the presence of Sp-1 in protein
DNA complexes (Fig. 2), free Sp-1 not bound to DNA was
not detected in the WEMSA assay (data was not shown).
This  was  as  expected  since  the  5%  polyacrylamide  gel
would be unlikely to retain proteins of relatively smaller
molecular  mass  such  as  uncomplexed  free  Sp-1.  As  an
additional  test  for  calcitriol-regulated  Sp-1  binding
activity,  we  conducted  a  parallel  WEMSA  analysis,  in
which  the  candidate  Sp-1-like  oligo  from  CD14  and  a
canonical Sp-1 oligo were used in parallel. Sp-1 binding to
both  the  candidate  and  canonical  sequences  displayed
similar  activities  in  control  and  calcitriol-treated  THP-1
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Fig. 1: CD14 proximal promoter.  This region spanning 469 bp
upstream of the transcriptional start site has been shown to be critical for
the induction of CD14 transcription in response to calcitriol. Putative Sp-1-
like transcription factor-binding sites in this region were identified using the
TFSEARCH program (http://www.cbrc.jp/research/db/TFSEARCH.html) and
are highlighted in boldface, underlined and labeled as (1) 5'-
GGGGGGTTGG-3' at position -345 to -336, (2) 5'-GTCCCTCCCCCT-3' at
position -159 to -148 , (3) 5'-AGGGGGCTGGC-3' at position -113 to -100 and





    
GGGATATAAGGTAGGGGGATTGGGGGGTTGGATAGTGCAGAGTATGGTATG 
                                                    -345     Sp-1 (1)     -336 
GCCTAAGGCACTGAGGATCATCCTTTTCCCACACCCACCAGAGAAGGCTTAG 
                  
GCTCCCGAGTCAACAGGGCATTCACGCCTGGGGCGCCTGAGTCATCAGGACA 
                                                                                  
CTGCCAGGAGACACAGAACCCTAGATGCCCTGCAGAATCCTTCCTGTTACGG 
                                                                                                                                  -159 
TCCCCCTCCCTGAAACATCCTTCATTGCAATATTTCCAGGAAAGGAAGGGGGC 
      Sp-1 (2)     -148                                                                                           -113   Sp-1 (3)  
TGGCTCGGAGGAAGAGAGGTGGGGAGGTGATCAGGGTTCACAGAGGAGGGA 




Fig. 2: WEMSA shows that Sp-1 binding to a specif ic site in the
CD14  promoter is regulated by calcitriol.  Serum starved THP-1 cells
were either treated or not with 100 nM calcitriol for 30 min followed by
preparation of nuclear extracts for WEMSA as described in Materials and
Methods. Nuclear extracts were incubated with four unlabelled oligos
denoting putative Sp-1-like transcription factor-binding sites in CD14
promoter (A) and DNA protein complexes were separated by non-denaturing
gel electrophoresis followed by transfer to nitrocellulose for Western
blotting for Sp-1 (B). The results shown are from one of three independent
experiments that yielded similar results.
A. Sp-1-like oligos  
 1. 5’-GGGGGGTTGG 
             2.  5’-TCCCCCTCCCT   
            3.  5’-GGGGGCTGGC 
            4.   5’-AGAGGTGGGGAGG 
 
                          
         B.   WEMSA 
                      Sp-1-like oligos        1           2                3             4 
                                                        
                      Calcitriol              -      +    -     +      -     +        -       + 
Sp-1 
Fig.  3:  Sp-1 displays similar binding activ ity  for both canonical
and candidate CD14 promoter Sp-1 DNA binding sequences.
Nuclear extract from calcitriol-treated and untreated THP-1 cells were used
for WEMSA analysis using non-labeled canonical (A) and (B) the candidate
CD14 promoter Sp-1 like oligo (sequence #4 from Fig. 1).
A.     WEMSA (Sp-1 canonical oligo) 
 




                           B.   WEMSA (Sp-1-like oligo) 
 
                                                            
                
   Sp-1 
Cacitriol                   -                                    + 
Cacitriol              -                               + 
   Sp-1 
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cells (Figs. 3A and B).
Validation of WEMSA Analysis of Calcitriol-Regulated Sp-1
Binding to a Site in the CD14 Promoter by Classical EMSA
The  analysis  of  calcitriol-regulated  Sp-1  binding  to  this
site in the  CD14 promoter using WEMSA suggested that
calcitriol  negatively regulated Sp-1 binding to  a  specific
DNA sequence  (Figs.  2  and 3).  In  order  to  validate  the
results of WEMSA, we used the same candidate Sp-1-like
oligo  (5'-AGAGGTGGGGAGG-3')  in  a  classical  EMSA.
THP-1  cells  were  treated  with  or  without  calcitriol  and
nuclear  extracts  were  prepared and incubated with this
Sp-1-like  sequence.  DNA-protein  complexes  were  then
separated  by  polyacrylamide  gel  electropheresis  for
EMSA.  The  results  shown in Fig.  4  clearly  demonstrate
clacitriol-mediated down-regulation of Sp-1 binding to the
candidate Sp-1 binding sequence in the  CD14  promoter,
thereby  corroborating  the  results  obtained  by  WEMSA.
Taken together,  these  results  confirm that the  candidate
Sp-1-like  binding site  located at  position  -91 to  -79 is  a
bona fide site for Sp-1 binding and that calcitriol reduces
Sp-1 binding to this position in the CD14 promoter.
The broad applicability of WEMSA is demonstrated by its
use  in  identifying  the  involvement  of  Sp-1,  and  in  an
earlier study,  the transcription factor CREB, in calcitriol-
mediated  CD14 expression  (6).  This  demonstrates  that
WEMSA provides a suitable substitute for classical EMSA
as a method to directly detect the potential involvement of
transcription  factors  and  their  cognate  DNA  binding
elements in gene regulation.  In addition, WEMSA offers
several advantages over classical EMSA which make this
technique  an  attractive  alternative  to  electrophoretic
mobility shift assays.  WEMSA is highly cost effective as
compared to  EMSA-based  supershifts,  as  WEMSA does
not  require  the  use  of  modified  oligonucleotides  and
antibodies can be used and recycled.
It is difficult to calculate the precise cost savings afforded
by  WEMSA  over  EMSA.  However,  our  best  estimate
would  be  around  30%.  This  is  based  on  the  cost  of
biotinylated  oligonucleotides  in  EMSA as  compared  to
unlabelled oligonucleotides in WEMSA and recycling of
primary  antibody  in  WEMSA  as  compared  to  EMSA.
Moreover,  antibodies  suitable  for  conducting  supershift
assays in EMSA are often limited, as these are required to
recognize epitopes under native conditions.  In WEMSA,
however,  any  antibody  that  is  suitable  for  conventional
Western blotting can be used. Thus, WEMSA provides an
attractive  option to classical  EMSA as a  method for  the
identification  of  transcription  factors  and  their  cognate
DNA  binding  elements  involved  in  regulating  gene
expression.
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Fig. 4: EMSA analysis confirms results obtained through
WEMSA. EMSA using labeled Sp-1-like oligo spanning positions 91 to -79
of the CD14 promoter. Serum starved THP-1 cells were either untreated or
treated with 100 nM calcitriol for 30 min followed by preparation of nuclear
extracts for EMSA as described in Materials and Methods. Lane 1, free
labeled oligo. Lane 2, nuclear extract of untreated cells combined with
Sp-1-like oligo. Lane 3, nuclear extract of calcitriol-treated cells combined
with Sp-1-like oligo. Lane 4 represents nuclear extract from untreated cells
combined with Sp-1-like oligo and unlabelled excess of Sp-1-like oligo. 
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PROTOCOLS
Western Blotting Electrophoresis Mobility Shift Assay (WEMSA) 
Reagents:
= Unlabelled and biotinylated Sp-1-like oligos for WEMSA and EMSA were from Invitrogen (Carlsbad,  CA).
Unlabelled and biotinylated canonical  Sp-1  oligos and EMSA kit  (EMSA Gel-Shift  Kit  #  AY 1288  P)  were
purchased from Panomics (Fremont, CA). Anti-Sp-1 antibody was from Upstate Cell Signaling Solutions (Lake
Placid, NY) 
= The human promonocytic cell line THP-1 was from American Type Culture Collection, Rockville, MD 
= Cell culture medium: RPMI 1640 medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum
(FBS), penicillin (100 units/ml) and streptomycin (100 g/ml).  
= 1 , 25-dihydroxyvitamin D 3 (calcitriol) was obtained from Calbiochem (San Diego, CA). 
Methods: 
Nuclear extract: 
= Nuclear fractions were prepared based on a protocol from the Skirball Institute of Biomolecular Medicine,
NYU Medical Center with minor modifications (6). 
Non-denaturing PAGE:
= Prepare 5% non-denaturing polyacrylamide gels in Tris-borate/EDTA buffer (0.1  M Tris,  0.09 M boric acid
containing 1mM EDTA) and store at 4°C. 
= Mix 5-10 g of nuclear extracts from treated and control cells with relevant oligos and poly (dI-dC) (1 g/ l) in  
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binding buffer (20 mM HEPES pH 7.9, 1 mM DTT, 0.1 mM EDTA, 50 mM KCl, 5% glycerol and 200 g/ml
BSA). 
= Add loading buffer to the above mixture to fractionate samples on gel at 4°C for 2-3 hrs using 100V. 
Western blotting:
= Transfer  PAGE separated proteins  onto  nitrocellulose  membrane  using  Western  blotting  semi-dry  transfer
apparatus. 
= Block the membrane and probe with anti-Sp-1-antibody as per the manufacturers instructions (Upstate Cell
Signaling Solutions). 
= Develop with ECL system.
Moeenrezakhanlou et al.  Identification of a Calcitriol-Regulated Sp-1 Site 
www.biologicalprocedures.com
